MedPharm's appointment with Destiny
28 Mar 2019Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.
Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, has appointed MedPharm as its expert partner to develop new topical formulations of the company’s novel XF-platform compounds.
These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of antimicrobial resistance (AMR).
The XF platform has already delivered a Phase II-ready candidate, XF-73 nasal gel, for the prevention of post-surgical infections that will begin Phase IIb testing in 2019. MedPharm will develop new formulations containing Destiny Pharma’s XF-platform compounds for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections. MedPharm is a well-established, global leader in topical product development with a track record in developing a wide variety of formulations, from early concept stage through clinical development to full product approval.
Eugene Ciolfi, President & CEO of MedPharm commented: “MedPharm is very excited to be a part of this project and working in close collaboration with Destiny to address this unmet medical need. Our rigorous methodology, incorporating our novel and world leading in vitro performance testing, will ensure that we deliver fully optimised formulations and de-risk these important development programmes.”
Neil Clark, CEO of Destiny Pharma commented: “We are pleased to be working with MedPharm and using their globally recognised expertise to develop effective, patient-friendly formulations from our novel XF-platform. There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced level of antimicrobial resistance. We look forward to developing improved, targeted formulations with MedPharm to take into future pre-clinical and clinical studies”.
Related news
Needle free: Erase wrinkles without injection
15 Jul 2019
Meet REVOLUTION BEYOND INNOVATION at Cphi Worldwide 2019, Booth No. 42C06
Read more
Eisai collaborates with University of Dundee on cancer drug discovery
10 Jul 2019
It is hoped that research into PROTACs will lead to new drug discoveries for proteins present in cancer, which are difficult to treat with conventional small molecule inhibitors.
Read more
Fresh data on protein interactions in Alzheimer’s disease
2 Jul 2019
Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.
Read more
Cyclolab Ltd strengthens its position in the market
1 Jul 2019
Cyclolab Ltd. is an R&D and cGMP manufacturing company focusing on all aspects of cyclodextrin science, manufacturing and applications for cyclodextrin, Dexolve, Sugammadex, formulation development, custom synthesis, Niemann Pick C.
Read more
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.
Read more
Clinical supply milestone reached for triple-negative breast cancer treatment
12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.
Read more
Trial finds vitamin D does not prevent type 2 diabetes in people at high risk
11 Jun 2019
No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.
Read more
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma
6 Jun 2019
Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.
Read more
Lilly gets its hands on non-opioid pain asset
4 Jun 2019
Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.
Read more
Updated clinical trial simulation software saves time and money
3 Jun 2019
One customer saves $25m and 3 years' development time in their clinical development strategy.
Read moreAre you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation